Olomorasib clinical trials

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

This study is testing a new drug, olomorasib, for a specific type of lung cancer (NSCLC) with a KRAS G12C gene change. It checks if olomorasib, combined with standard treatments, works better than standard treatments alone for people with either resected or unresectable cancer.